Laboratory Study Of The Combinative Therapy With Aminoguanidine And Tetromethylpragine On Type Ⅱ Diabetes Mellitus

OBJECTIVE:This study was aimed to explore the pathogenesis of type Ⅱ diabetes mellitus and the treatment mechanism of aminoguanidine combined with tetromethylpragine in diabetic Wistar rats induced by streptozotocin (STZ), recording the changes of insulin signaling molecules in gene transcription in leucocytes of peripheral blood.METHODS:The diabetic model of newborn Wistar rats was duplicated with streptozotocin (100mg/kg) intraperitoneally, an model of type Ⅱ diabetes mellitus. The rats were raised for 3 months, and those whose fasting plasma glucose higher than or equal to 7.0mmol/L or whose 2 hours postprandial blood glucose higher than or equal to 11.1mmol/L in glucose tolerance test were selected. Rats were divided into 6 groups randomly: control group, diabetic group, aminoguanidine group, tetromethylpragine group, combination of aminoguanidine and tetromethylpragine, and dimethylbiguanide group. The mRNA expressions of inducible nitric oxide synthase (iNOS mRNA), phosphatidylinositol 3-kinase a subunit (PI-3K P85α mRNA) , protein kinase B α (PKBα mRNA), protein kinase C β (PKCβ mRNA), insulin-like growth factor-1 (IGF-1 mRNA) in leucocytes of peripheral blood were detected each month from the tail vein. Blood glucose levels on an empty stomach, insulin, glycosylated serum protein (GSP), NO, MDA and SOD were examined. Biochemical indicators and expression of mRNA of molecules in insulin signal...